Auris Medical Holding

US: EARS

$3m market cap

$0.4 last close

Auris Medical is a Swiss biopharmaceutical company developing neurotology and CNS therapeutics. It is developing intranasal betahistine in a Phase I trial for mental disorder supportive care and is in Phase II for vertigo; both are designed to demonstrate proof-of-concept.

Investment summary

Auris Medical is a clinical-stage biopharmaceutical company developing pharmacotherapies for inner ear and CNS disorders. Its primary focus is on the development of AM-125 (intranasal betahistine) for the treatment of acute vertigo. Oral betahistine dihydrochloride has been prescribed in Europe for decades for all types of vertigo, with an average 26% market share, but is not available in the US. Auris has initiated its Phase II clinical trial in 118 patients with surgically induced acute vertigo. Enrollment has been affected by the coronavirus pandemic but the company believes interim data may be available in Q320 at the earliest. It is also developing AM-201, an intranasal betahistine formulation in Phase Ib, for co-administration with olanzapine to counteract adverse effects, especially weight gain. Data are expected in the coming weeks.

Y/E Dec
Revenue (CHFm)
EBITDA (CHFm)
PBT (CHFm)
EPS (CHFc)
P/E (x)
P/CF (x)
2018A 0.0 (11.0) (12.0) (1532.81) N/A N/A
2019A 0.0 (7.3) (7.3) (243.24) N/A N/A
2020E 0.0 (10.2) (10.9) (247.30) N/A N/A
2021E 0.0 (16.3) (17.7) (387.68) N/A N/A
Industry outlook

Acute vertigo/dizziness is one of the most common causes of visits to A&E with roughly 2.6m visits associated with the condition each year.

Last updated on 14/03/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (CHFm) 8.8
Forecast gearing ratio (%) 179
Price performance
%
1m
3m
12m
Actual 15.5 (41.4) (87.8)
Relative* 13.4 (30.3) (87.1)
52-week high/low US$2.0/US$0.2
*% relative to local index
Key management
Thomas Meyer CEO
Elmar Schaerli CFO